Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tardive Dyskinesia Therapeutics Market

Tardive Dyskinesia Therapeutics Market Trends

Report ID: GMI9586
Published Date: May 2024
Report Format: PDF

Download Free Sample

Tardive Dyskinesia Therapeutics Market Trends

The rising prevalence of tardive dyskinesia (TD) is significantly propelling the growth of the TD therapeutics market. As per recent statistics it has been indicated that approximately 20-30% of individuals on long-term antipsychotic therapy develop TD, highlighting the widespread impact of this condition.

For instance, as per the report published in Healthline in February 2022, in the U.S. alone, an estimated 500,000 to 700,000 people are affected by TD. This growing patient population drives the demand for effective therapeutic options, prompting increased research and development efforts. Thus, the introduction of novel treatments such as VMAT2 inhibitors like valbenazine and deutetrabenazine, has enhanced symptomatic management, thereby contributing to market growth.
Additionally, the increase in awareness among healthcare providers and improved diagnostic techniques are leading to more timely and accurate diagnoses, further boosting the demand for TD therapeutics.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global tardive dyskinesia therapeutics market size was valued at USD 3.1 billion in 2023 and will grow at 7.1% CAGR during 2024-2032, driven by the increasing prevalence of tardive dyskinesia.

The valbenazine drug type segment in the market recorded USD 1.6 billion in 2023 and will grow rapidly through 2032, as the drug has demonstrated significant efficacy in reducing the symptoms of tardive dyskinesia in clinical trials.

North America secured 44.2% of the tardive dyskinesia therapeutics market share in 2023 and will expand at a steady pace through 2032, owing to the availability of well-established healthcare infrastructure and access to medical facilities.

H. Lundbeck A/S, Luye Pharma Group, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., SteriMax Inc., SOM Biotech, and Teva Neuroscience, Inc. among others.